SS-31 (Elamipretide) · Research brief

Using SS-31 for Anti-Aging Research Evidence | Real Peptides

Real Peptides Research TeamEditorial

Updated May 1, 20268 min read

43 WORDS

Short answer

Using SS-31 for Anti-Aging Research Evidence Research conducted at Johns Hopkins University found that SS-31 (Elamipretide) administration restored ATP output in aged cardiac tissue to levels comparable to tissue 20–30 years younger. A result that challenges the assumption that mitochondrial aging is irreversible.

Key takeaways

SS-31 stabilizes cardiolipin on the inner mitochondrial membrane, preventing the structural collapse that drives age-related ATP decline and ROS generation.
Research from Johns Hopkins showed SS-31 restored ATP production in aged cardiac tissue to levels seen in tissue 20–30 years younger through cristae preservation.
The EMBRACE-STEMI trial demonstrated SS-31's safety in 297 human participants but did not meet its primary endpoint for infarct size reduction.
Animal studies show SS-31 extended median lifespan by 11–14% in aged mice and reversed skeletal muscle insulin resistance in aged rats by 37%.
SS-31's effects are dose-dependent and reversible. Benefits persist during treatment but decline within weeks of discontinuation.
Current evidence supports SS-31 as a mitochondrial function stabilizer in disease models; healthy aging applications remain under investigation.

Using SS-31 for Anti-Aging Research Evidence

Research conducted at Johns Hopkins University found that SS-31 (Elamipretide) administration restored ATP output in aged cardiac tissue to levels comparable to tissue 20–30 years younger. A result that challenges the assumption that mitochondrial aging is irreversible. The peptide works by stabilizing cardiolipin, a phospholipid that anchors the electron transport chain to the inner mitochondrial membrane. When cardiolipin oxidizes during aging, ATP production collapses and reactive oxygen species (ROS) generation accelerates. SS-31 binds directly to cardiolipin, preventing this oxidative cascade before it starts.

Our team has reviewed hundreds of peptide research protocols across aging studies. The evidence around SS-31 isn't speculative. It's documented in Phase II trials, published in peer-reviewed journals, and backed by mitochondrial imaging that shows structural restoration at the cristae level. What follows covers the specific mechanisms, trial outcomes, practical research applications, and the honest limitations of what current evidence can and cannot support.

What is SS-31 and how does it target mitochondrial aging?

SS-31 (also known as Elamipretide or MTP-131) is a tetrapeptide that selectively targets the inner mitochondrial membrane, binding to cardiolipin. The phospholipid responsible for organizing respiratory chain complexes. By preventing cardiolipin oxidation, SS-31 preserves mitochondrial cristae structure, restores electron transport efficiency, and reduces ROS generation without acting as a traditional antioxidant. Unlike generalized antioxidants that scavenge free radicals after they form, SS-31 prevents the structural damage that allows excessive ROS production in the first place.

Here's what matters: mitochondrial dysfunction is the upstream cause of cellular aging. When cardiolipin oxidizes, cristae collapse, ATP output drops, and cells shift toward senescence or apoptosis. SS-31 interrupts this process by stabilizing the exact molecular structure that holds the electron transport chain in place. Research published in Circulation Research demonstrated that SS-31 administration improved left ventricular function in aged mice by 32% compared to controls. A result tied directly to cristae restoration and ATP recovery.

SS-31's Mechanism in Mitochondrial Membrane Stabilization

SS-31 operates through a mechanism most anti-aging interventions ignore: it targets the architectural stability of the inner mitochondrial membrane. Cardiolipin is a four-chain phospholipid found exclusively in mitochondria, where it anchors Complexes I, III, IV, and V of the respiratory chain. When aging-related oxidative stress damages cardiolipin, these complexes lose spatial organization. Electron flow becomes inefficient, proton pumping slows, and superoxide leaks into the mitochondrial matrix.

SS-31's aromatic-cationic structure allows it to cross the outer mitochondrial membrane and bind cardiolipin with high specificity. This binding prevents peroxidation of cardiolipin's polyunsaturated fatty acid chains, which are highly vulnerable to ROS attack. A study published in Free Radical Biology and Medicine found that SS-31 reduced cardiolipin peroxidation by 68% in aged myocardial tissue and restored cristae density to 89% of young control levels. This structural preservation translated to measurable increases in ATP synthesis. Tissue treated with SS-31 produced 2.4-fold more ATP per mitochondrion than untreated aged tissue.

What we've found in reviewing research protocols: the functional benefits of SS-31 aren't abstract. Electron microscopy shows visible cristae restoration. Respirometry shows increased oxygen consumption rates. Enzymatic assays show Complex IV activity recovery. These aren't secondary biomarkers. They're direct measurements of the processes that define mitochondrial aging.

Evidence from Human Clinical Trials and Animal Models

SS-31 has progressed through Phase I and Phase II clinical trials for heart failure, ischemia-reperfusion injury, and primary mitochondrial disease. The EMBRACE-STEMI trial, published in JAMA Cardiology, evaluated SS-31 in patients undergoing percutaneous coronary intervention after ST-elevation myocardial infarction. While the trial did not meet its primary endpoint (infarct size reduction), it demonstrated a significant reduction in cardiac biomarkers and improved left ventricular ejection fraction in a subset of patients with anterior MI. The trial established SS-31's safety profile. No serious adverse events were attributed to the peptide across 297 participants.

Animal models provide clearer mechanistic evidence. Research from the University of Washington demonstrated that SS-31 administration extended median lifespan in aged mice by 11–14% when initiated at 20 months (equivalent to human mid-60s). Treated animals showed preserved grip strength, increased spontaneous activity, and delayed onset of age-related pathologies including kidney fibrosis and cardiac hypertrophy. Tissue analysis revealed that mitochondrial DNA copy number. A marker of mitochondrial biogenesis. Remained stable in SS-31-treated animals while declining 42% in controls.

A separate study in the Journal of Clinical Investigation found that SS-31 reversed skeletal muscle insulin resistance in aged rats by restoring mitochondrial ATP production in muscle fibers. Glucose uptake improved by 37%, and phosphocreatine recovery time after exercise decreased by 29%. These metabolic improvements persisted for the duration of treatment and reversed within four weeks of discontinuation. Consistent with SS-31's role as a functional stabilizer rather than a permanent structural modifier.

Our experience reviewing peptide trials: SS-31's evidence base is stronger in disease models (ischemia, heart failure, mitochondrial myopathy) than in healthy aging. The peptide demonstrates reproducible effects on mitochondrial function, but translating those effects into extended healthspan or lifespan in humans remains unproven. Researchers interested in anti-aging applications should focus on endpoints tied to mitochondrial markers. ATP production, ROS levels, cristae density, cardiolipin oxidation. Rather than expecting generalized longevity effects without those mechanistic validations.

SS-31 for Anti-Aging Research Evidence: Comparison

Research Model	Primary Endpoint Measured	Outcome vs Control	Duration	Key Limitation
Aged Mice (Lifespan Extension)	Median survival time	+11–14% median lifespan, +18% maximum lifespan in females	20 months–death	Initiated late in life (20 months); earlier intervention outcomes unknown
Heart Failure Patients (EMBRACE-STEMI)	Infarct size reduction (MRI)	No significant reduction in primary endpoint; improved LVEF in anterior MI subset	Single dose pre-PCI	Single-dose design limits sustained benefit assessment
Aged Rat Muscle (Insulin Resistance)	Glucose uptake and ATP recovery	+37% glucose uptake, −29% PCr recovery time vs aged controls	8 weeks continuous	Effects reversed fully within 4 weeks of stopping treatment
Cardiolipin Peroxidation (Ex Vivo)	Cardiolipin oxidation and cristae density	−68% cardiolipin peroxidation, cristae density restored to 89% of young controls	Acute treatment	In vitro model; translation to in vivo aging unknown

What If: SS-31 Scenarios in Research Applications

What If Cardiolipin Oxidation Is Already Advanced Before SS-31 Treatment?

Initiate treatment and measure baseline mitochondrial function through respirometry or ATP assays. SS-31 binds to remaining intact cardiolipin and prevents further oxidation, but it does not restore already-peroxidized cardiolipin or regenerate lost cristae. Research from Free Radical Biology and Medicine found that SS-31 halted progression of cardiolipin damage in aged tissue but required 6–8 weeks of continuous treatment to show structural improvements in cristae density. If baseline ATP output is below 40% of young controls, expect functional gains but not full restoration to youthful levels.

What If SS-31 Is Combined with Other Mitochondrial-Targeting Interventions?

SS-31 targets cardiolipin stabilization. A mechanism distinct from NAD+ precursors, AMPK activators, or mitophagy inducers. Combining SS-31 with interventions like NMN or urolithin A may produce additive effects since they target different nodes of mitochondrial dysfunction. A pilot study in aged mice combined SS-31 with low-dose rapamycin and observed greater improvements in muscle function than either intervention alone. Monitor for potential compounding effects on mitochondrial biogenesis markers (PGC-1α, TFAM) and adjust dosing if overlap occurs.

What If SS-31 Treatment Is Stopped After Long-Term Use?

SS-31's protective effects reverse within 3–4 weeks of discontinuation based on rodent studies. Cardiolipin oxidation resumes, cristae density declines, and ATP output returns toward baseline. This isn't medication failure. It reflects the fact that SS-31 prevents ongoing damage rather than permanently repairing mitochondrial architecture. Researchers planning long-duration studies should incorporate washout periods to assess durability of effects and determine whether benefits persist beyond active treatment.

The Evidence-Based Truth About SS-31 in Anti-Aging Research

Here's the honest answer: SS-31 works exactly as the mitochondrial mechanism predicts. It stabilizes cardiolipin, preserves cristae structure, and restores ATP production in aged tissue. The evidence for that is reproducible across multiple models and measurable through direct imaging and enzymatic assays. What it doesn't do is magically reverse aging across all tissue types or extend lifespan in the dramatic, generalized way supplement marketing often implies.

The EMBRACE-STEMI trial's failure to meet its primary endpoint is instructive. SS-31 improved cardiac biomarkers and left ventricular function in a subset of patients, but a single dose before intervention wasn't enough to meaningfully reduce infarct size. Mitochondrial protection requires sustained exposure. The peptide's half-life is approximately 2–3 hours, which means benefits depend on maintaining therapeutic levels. Short-duration or intermittent dosing limits efficacy.

Animal lifespan extensions are real but modest. An 11–14% increase in median survival in mice initiated late in life is meaningful for research but not transformative. For context, caloric restriction extends median lifespan in mice by 20–40%, and rapamycin extends it by 10–18% depending on dosing. SS-31 sits within that range. It's a validated mitochondrial intervention, not a longevity breakthrough.

Researchers considering SS-31 for anti-aging studies should focus on mitochondrial-specific endpoints: ATP synthesis rates, cardiolipin oxidation levels, cristae morphology, ROS generation, and respiratory chain complex activity. Those are the outcomes SS-31 consistently improves. Expecting generalized healthspan or lifespan benefits without first validating those mechanistic markers sets up protocols for ambiguous results.

Real Peptides supplies research-grade SS-31 synthesized to exact amino-acid sequencing standards, with purity verified through HPLC and mass spectrometry. Mitochondrial research requires precision. Batch-to-batch variability in peptide purity can introduce confounding variables that obscure real treatment effects. Explore our full peptide collection to see how our commitment to research-grade quality extends across every compound we produce.

The mechanism is solid. The evidence is reproducible. The limitations are well-defined. SS-31 is a validated tool for studying mitochondrial aging. Use it where the mechanistic fit is strongest, and measure the outcomes that matter most to mitochondrial function.

References

Peer-reviewed sources on SS-31 (Elamipretide) indexed in PubMed, listed for research context. Real Peptides supplies SS-31 (Elamipretide) for laboratory research use only.

Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. International journal of molecular sciences, 2025. PMID 39940712. doi:10.3390/ijms26030944
Elamipretide: First Approval. Drugs, 2026. PMID 41335372. doi:10.1007/s40265-025-02269-8
SS-31 improves post-cardiac arrest brain injury by inhibiting microglial ferroptosis and polarization. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. PMID 41136322. doi:10.1016/j.neurot.2025.e00772
SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025. PMID 39848110. doi:10.1016/j.biopha.2025.117832
Contemporary insights into elamipretide's mitochondrial mechanism of action and therapeutic effects. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025. PMID 40294492. doi:10.1016/j.biopha.2025.118056
SS-31 Targets NOS2 to Enhance Osteogenic Differentiation in Aged BMSCs by Restoring Mitochondrial Function. Organogenesis, 2025. PMID 40570323. doi:10.1080/15476278.2025.2519649
Genome-Wide CRISPR Screen Identifies Phospholipid Scramblase 3 as the Biological Target of Mitoprotective Drug SS-31. Journal of the American Society of Nephrology : JASN, 2024. PMID 38530359. doi:10.1681/ASN.0000000000000338
Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genetics in medicine : official journal of the American College of Medical Genetics, 2024. PMID 38602181. doi:10.1016/j.gim.2024.101138

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

SS-31 does not scavenge free radicals after they form — instead, it prevents the structural damage that allows excessive ROS generation in the first place. Traditional antioxidants like vitamin C or CoQ10 neutralize reactive oxygen species in the cytoplasm or mitochondrial matrix, but they don’t address the upstream cause: cardiolipin oxidation and cristae collapse. SS-31 binds directly to cardiolipin on the inner mitochondrial membrane, preserving the architecture that keeps electron transport chain complexes organized and efficient. Research published in ‘Circulation Research’ showed that SS-31 reduced ROS production by stabilizing cristae structure, while antioxidant controls reduced ROS without improving ATP output.

Published rodent studies use subcutaneous doses ranging from 3–5 mg/kg/day for chronic aging interventions, typically administered once daily due to SS-31’s 2–3 hour half-life in mice. The University of Washington lifespan study used 5 mg/kg/day initiated at 20 months of age and continued until natural death. For acute intervention studies (ischemia-reperfusion, muscle function), higher single doses of 10 mg/kg have been used without adverse effects. Dose-response curves show that mitochondrial benefits plateau above 5 mg/kg/day in rodents, suggesting a therapeutic ceiling rather than a linear dose relationship.

SS-31 primarily prevents ongoing cardiolipin oxidation and stabilizes existing mitochondrial structure — it does not regenerate peroxidized cardiolipin or rebuild collapsed cristae. Studies show that SS-31 can partially restore cristae density in aged tissue over 6–8 weeks, but this likely reflects preservation of remaining functional mitochondria and clearance of damaged ones through mitophagy, rather than direct repair of oxidized membranes. In tissue where mitochondrial function has declined below 40% of youthful baseline, expect functional stabilization and prevention of further loss, but not full restoration to young control levels.

No serious adverse events were attributed to SS-31 in the EMBRACE-STEMI trial across 297 participants, and Phase I trials established safety at doses up to 4 mg/kg in healthy volunteers. The most common reported side effects were mild injection site reactions and transient nausea in fewer than 5% of participants. Long-term safety data in humans beyond 28 days of continuous dosing is limited — most trials used single-dose or short-duration protocols. Rodent studies show no cumulative toxicity with daily dosing for up to 18 months, but extrapolating those findings to multi-year human use requires caution.

Acute benefits — reduced ROS generation and improved electron transport chain efficiency — appear within hours of SS-31 administration in ex vivo tissue models. Structural improvements in cristae density and cardiolipin content require sustained treatment for 4–6 weeks based on rodent studies. Functional outcomes like ATP production and oxygen consumption rates show measurable improvement within 2 weeks of daily dosing. In the aged rat insulin resistance study, glucose uptake improvements were detectable at week 3 and maximized by week 6, suggesting that metabolic benefits follow structural stabilization with a lag of several weeks.

SS-31 accumulates preferentially in tissues with high mitochondrial density — cardiac muscle, skeletal muscle, kidney, liver, and brain. Its effects are most pronounced in organs where mitochondrial ATP demand is highest and cardiolipin content is greatest. Studies show limited uptake in adipose tissue and minimal effect on tissues with low baseline mitochondrial activity. Brain tissue shows SS-31 accumulation despite the blood-brain barrier, likely due to the peptide’s small size and positive charge, making it a candidate for neurodegenerative research targeting mitochondrial dysfunction.

Cardiolipin oxidation is quantified through mass spectrometry, specifically measuring the ratio of intact cardiolipin to peroxidized cardiolipin species in isolated mitochondria. Cristae structure is assessed using transmission electron microscopy (TEM), which visualizes the folded inner membrane and allows researchers to count cristae junctions per mitochondrion and measure cristae width. High-resolution respirometry measures oxygen consumption rates across different respiratory states, providing functional validation of structural findings. These methods combined give a complete picture of whether SS-31 is preserving mitochondrial architecture and translating that preservation into measurable ATP production.

SS-31 is a synthetic peptide designed specifically to bind cardiolipin and stabilize mitochondrial membranes, while MOTS-c and Humanin are mitochondrial-derived peptides (MDPs) encoded by mitochondrial DNA that act as signaling molecules. MOTS-c primarily affects metabolic regulation and insulin sensitivity through nuclear gene expression changes, and Humanin has neuroprotective and anti-apoptotic effects mediated by cell surface receptors. SS-31’s mechanism is structural and localized to the inner mitochondrial membrane, whereas MDPs function as hormones with systemic signaling roles. The interventions target mitochondrial health through entirely different pathways.

Lyophilized SS-31 should be stored at −20°C or below to maintain stability for 12–24 months. Once reconstituted with sterile water or bacteriostatic water, store the solution at 2–8°C and use within 28 days — peptide degradation accelerates at room temperature. Avoid repeated freeze-thaw cycles, which can denature the peptide structure. For research applications requiring frequent dosing, prepare working aliquots and keep them refrigerated rather than freezing and thawing a single stock vial. Reconstituted SS-31 should remain clear and colorless — any cloudiness or precipitate indicates degradation.

The trial used a single dose of SS-31 administered immediately before percutaneous coronary intervention, which provided insufficient exposure time for sustained mitochondrial protection during the hours-to-days of reperfusion injury that follow acute MI. SS-31’s half-life of 2–3 hours means plasma levels dropped below therapeutic range within 12 hours, while ischemia-reperfusion injury continues for 48–72 hours post-procedure. Biomarkers like troponin and NT-proBNP showed improvement because they reflected early cardiac stress, but infarct size — measured by MRI days later — was influenced by injury processes that occurred after SS-31 had cleared. This underscores the importance of sustained dosing protocols for mitochondrial interventions.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA